Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line 
Establishment and Validation of Their Sensitivity to EGFR Inhibitors

Non-small Cell Lung Cancer Cell Line PC-9 Drug-resistant Mutant Cell Line 
Establishment and Validation of Their Sensitivity to EGFR Inhibitors

Background and objective Mutations in the structural domain of the epidermal growth factor receptor (EGFR) kinase represent a critical pathogenetic factor in non-small cell lung cancer (NSCLC). Small-molecule EGFR-tyrosine kinase inhibitors (TKIs) serve as first-line therapeutic agents for the treat...

Full description

Bibliographic Details
Main Authors: Tao HU, Yang LOU, Mingbo SU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2024-11-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
crispr/cas9 technology
egfr mutation
egfr inhibitors
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2024.101.31

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2024.101.31

Similar Items